Pediatric ependymoma: an overview of a complex disease

[1]  F. Andreiuolo,et al.  Supratentorial ependymoma in childhood: more than just RELA or YAP , 2021, Acta Neuropathologica.

[2]  S. Pfister,et al.  The AIEOP 2nd series of children and adolescents intracranial Ependymoma. An integrated molecular and clinical characterization with a long-term follow-up. , 2020, Neuro-oncology.

[3]  K. Aldape,et al.  High level MYCN amplification and distinct methylation signature define an aggressive subtype of spinal cord ependymoma , 2020, Acta Neuropathologica Communications.

[4]  T. Jacques,et al.  A retrospective analysis of recurrent pediatric ependymoma reveals extremely poor survival and ineffectiveness of current treatments across central nervous system locations and molecular subgroups , 2020, Pediatric blood & cancer.

[5]  F. Andreiuolo,et al.  CDKN2A deletion in supratentorial ependymoma with RELA alteration indicates a dismal prognosis: a retrospective analysis of the HIT ependymoma trial cohort , 2020, Acta Neuropathologica.

[6]  F. Andreiuolo,et al.  Ependymomas in infancy: underlying genetic alterations, histological features, and clinical outcome , 2020, Child's Nervous System.

[7]  K. Kahle,et al.  Comparison of epidemiology, treatments, and outcomes in pediatric versus adult ependymoma , 2020, Neuro-oncology advances.

[8]  M. Kool,et al.  Molecular characterization of histopathological ependymoma variants , 2020, Acta Neuropathologica.

[9]  Anas Abdallah,et al.  Long-Term Surgical Resection Outcomes of Pediatric Myxopapillary Ependymoma: Experience of Two Centers and Brief Literature Review. , 2019, World neurosurgery.

[10]  L. Klein-Hitpass,et al.  Improved risk-stratification for posterior fossa ependymoma of childhood considering clinical, histological and genetic features – a retrospective analysis of the HIT ependymoma trial cohort , 2019, Acta Neuropathologica Communications.

[11]  A. Raghunathan,et al.  Spinal Cord Ependymomas With MYCN Amplification Show Aggressive Clinical Behavior. , 2019, Journal of neuropathology and experimental neurology.

[12]  S. Mueller,et al.  A systematic review and meta-analysis of outcomes in pediatric, recurrent ependymoma , 2019, Journal of Neuro-Oncology.

[13]  David T. W. Jones,et al.  MYCN amplification drives an aggressive form of spinal ependymoma , 2019, Acta Neuropathologica.

[14]  T. Merchant,et al.  Molecular Grouping and Outcomes of Young Children with Newly Diagnosed Ependymoma Treated on the Multi-Institutional SJYC07 Trial. , 2019, Neuro-oncology.

[15]  M. Kool,et al.  Newly Diagnosed Metastatic Intracranial Ependymoma in Children: Frequency, Molecular Characteristics, Treatment, and Outcome in the Prospective HIT Series. , 2019, The oncologist.

[16]  T. Zhou,et al.  Conformal Radiation Therapy for Pediatric Ependymoma, Chemotherapy for Incompletely Resected Ependymoma, and Observation for Completely Resected, Supratentorial Ependymoma. , 2019, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[17]  M. Rosenblum,et al.  Clinicopathologic features of anaplastic myxopapillary ependymomas , 2019, Brain pathology.

[18]  Naoki Kagawa,et al.  Significance of molecular classification of ependymomas: C11orf95-RELA fusion-negative supratentorial ependymomas are a heterogeneous group of tumors , 2018, Acta Neuropathologica Communications.

[19]  M. Kool,et al.  Diagnostics of pediatric supratentorial RELA ependymomas: integration of information from histopathology, genetics, DNA methylation and imaging , 2018, Brain pathology.

[20]  C. Sommer,et al.  Childhood supratentorial ependymomas with YAP1‐MAMLD1 fusion: an entity with characteristic clinical, radiological, cytogenetic and histopathological features , 2018, Brain pathology.

[21]  G. Reifenberger,et al.  DNA methylation-based classification of ependymomas in adulthood: implications for diagnosis and treatment , 2018, Neuro-oncology.

[22]  T. Pietsch,et al.  MRI Phenotype of RELA-fused Pediatric Supratentorial Ependymoma , 2018, Clinical Neuroradiology.

[23]  Martin Sill,et al.  Heterogeneity within the PF-EPN-B ependymoma subgroup , 2018, Acta Neuropathologica.

[24]  David T. W. Jones,et al.  Molecular heterogeneity and CXorf67 alterations in posterior fossa group A (PFA) ependymomas , 2018, Acta Neuropathologica.

[25]  David T. W. Jones,et al.  Feasibility of real-time molecular profiling for patients with newly diagnosed glioblastoma without MGMT promoter hypermethylation—the NCT Neuro Master Match (N2M2) pilot study , 2018, Neuro-oncology.

[26]  David T. W. Jones,et al.  Novel, improved grading system(s) for IDH-mutant astrocytic gliomas , 2018, Acta Neuropathologica.

[27]  G. Reifenberger,et al.  EANO guidelines for the diagnosis and treatment of ependymal tumors. , 2018, Neuro-oncology.

[28]  M. Gilbert,et al.  Ependymomas arising outside of the central nervous system: A case series and literature review , 2018, Journal of Clinical Neuroscience.

[29]  B. Pollo,et al.  Role of Immunohistochemistry in the Identification of Supratentorial C11ORF95-RELA Fused Ependymoma in Routine Neuropathology , 2017, The American journal of surgical pathology.

[30]  Anne Song,et al.  Therapeutic Targeting of Ependymoma as Informed by Oncogenic Enhancer Profiling , 2017, Nature.

[31]  D. Johnston,et al.  Immunohistochemical analysis of H3K27me3 demonstrates global reduction in group-A childhood posterior fossa ependymoma and is a powerful predictor of outcome , 2017, Acta Neuropathologica.

[32]  S. Khatua,et al.  Progression‐free survival of children with localized ependymoma treated with intensity‐modulated radiation therapy or proton‐beam radiation therapy , 2017, Cancer.

[33]  Richard C. McEachin,et al.  Lowered H3K27me3 and DNA hypomethylation define poorly prognostic pediatric posterior fossa ependymomas , 2016, Science Translational Medicine.

[34]  P. Ferroli,et al.  Final results of the second prospective AIEOP protocol for pediatric intracranial ependymoma. , 2016, Neuro-oncology.

[35]  T. Hortobágyi,et al.  Therapeutic Impact of Cytoreductive Surgery and Irradiation of Posterior Fossa Ependymoma in the Molecular Era: A Retrospective Multicohort Analysis. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  A. Jouvet,et al.  Supratentorial clear cell ependymomas with branching capillaries demonstrate characteristic clinicopathological features and pathological activation of nuclear factor-kappaB signaling. , 2016, Neuro-oncology.

[37]  M. Milano,et al.  Myxopapillary ependymoma: a SEER analysis of epidemiology and outcomes , 2016, Journal of Neuro-Oncology.

[38]  Emma C. Celano,et al.  Spinal cord ependymoma: a review of the literature and case series of ten patients , 2016, Journal of Neuro-Oncology.

[39]  Gary D Bader,et al.  Molecular Classification of Ependymal Tumors across All CNS Compartments, Histopathological Grades, and Age Groups. , 2015, Cancer cell.

[40]  M. Preusser,et al.  Long-term outcome of patients with spinal myxopapillary ependymoma: treatment results from the MD Anderson Cancer Center and institutions from the Rare Cancer Network. , 2015, Neuro-oncology.

[41]  L. Klein-Hitpass,et al.  Supratentorial ependymomas of childhood carry C11orf95–RELA fusions leading to pathological activation of the NF-κB signaling pathway , 2014, Acta Neuropathologica.

[42]  Gary D Bader,et al.  Epigenomic alterations define lethal CIMP-positive ependymomas of infancy , 2014, Nature.

[43]  Li Ding,et al.  C11orf95-RELA fusions drive oncogenic NF-κB signaling in ependymoma , 2014, Nature.

[44]  C. Ames,et al.  Tumor control after surgery for spinal myxopapillary ependymomas: distinct outcomes in adults versus children: a systematic review. , 2013, Journal of neurosurgery. Spine.

[45]  T. Merchant,et al.  Distinct disease-risk groups in pediatric supratentorial and posterior fossa ependymomas , 2012, Acta Neuropathologica.

[46]  Gary D Bader,et al.  Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma. , 2011, Cancer cell.

[47]  Richard G Grundy,et al.  Histopathological grading of pediatric ependymoma: reproducibility and clinical relevance in European trial cohorts , 2011, Journal of Negative Results in BioMedicine.

[48]  T. Pietsch,et al.  Ependymoma of the spinal cord in children and adolescents: a retrospective series from the HIT database. , 2010, Journal of neurosurgery. Pediatrics.

[49]  J. Villano,et al.  Clinical presentation, histology, and treatment in 430 patients with primary tumors of the spinal cord, spinal meninges, or cauda equina. , 2010, Journal of neurosurgery. Spine.

[50]  P. Lichter,et al.  Molecular staging of intracranial ependymoma in children and adults. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[51]  J. Lowe,et al.  Pediatric Ependymoma: Biological Perspectives , 2009, Molecular Cancer Research.

[52]  Kristin L. Sainani,et al.  Incidence patterns for ependymoma: a surveillance, epidemiology, and end results study. , 2009, Journal of neurosurgery.

[53]  T. Merchant,et al.  Conformal radiotherapy after surgery for paediatric ependymoma: a prospective study. , 2009, The Lancet. Oncology.

[54]  Sairos Safai,et al.  Proton radiotherapy for childhood ependymoma: initial clinical outcomes and dose comparisons. , 2008, International journal of radiation oncology, biology, physics.

[55]  T. Zhou,et al.  The prognostic value of histological grading of posterior fossa ependymomas in children: a Children's Oncology Group study and a review of prognostic factors , 2008, Modern Pathology.

[56]  K. Dieckmann,et al.  Role of radiotherapy in anaplastic ependymoma in children under age of 3 years: results of the prospective German brain tumor trials HIT-SKK 87 and 92. , 2005, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

[57]  Amar Gajjar,et al.  Radial glia cells are candidate stem cells of ependymoma. , 2005, Cancer cell.

[58]  D. Ellison,et al.  Genomic imbalances in pediatric intracranial ependymomas define clinically relevant groups. , 2002, The American journal of pathology.

[59]  T. Merchant.  Current management of childhood ependymoma. , 2002, Oncology.

[60]  T. Barth,et al.  Low Frequency of Chromosomal Imbalances in Anaplastic Ependymomas as Detected by Comparative Genomic Hybridization , 2001, Brain pathology.

[61]  D. Frappaz,et al.  Postoperative chemotherapy without irradiation for ependymoma in children under 5 years of age: a multicenter trial of the French Society of Pediatric Oncology. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[62]  K. Koeller,et al.  Neoplasms of the spinal cord and filum terminale: radiologic-pathologic correlation. , 2000, Radiographics : a review publication of the Radiological Society of North America, Inc.

[63]  G. Reifenberger,et al.  Molecular genetic analysis of ependymal tumors. NF2 mutations and chromosome 22q loss occur preferentially in intramedullary spinal ependymomas. , 1999, The American journal of pathology.

[64]  P. Celli,et al.  [Neurinomas and ependymomas of the cauda equina. A review of the clinical characteristics]. , 1997, Minerva chirurgica.

[65]  B. Scheithauer,et al.  Myxopapillary ependymoma. A clinicopathologic and immunocytochemical study of 77 cases , 1985, Cancer.

[66]  Jill S Barnholtz-Sloan,et al.  CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010–2014 , 2017, Neuro-oncology.

[67]  R. Beroukhim,et al.  Myxopapillary ependymomas in children: imaging, treatment and outcomes , 2015, Journal of Neuro-Oncology.

[68]  D. Louis.  WHO classification of tumours of the central nervous system , 2007 .